BCL2L1 and renal cell carcinoma: However, activation of caspases and mitochondrial pathways has been reported in neuroblastoma cells in response to the combination of S63845 with the Bcl-xL inhibitor A1331852 [72], as well as in renal cell carcinoma cells in response to the combination of ABT-263 with TW-37 (targeting Mcl-1, Bcl-xL, and Bcl-2) [73].